How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/calcipotriene-and-betamethasone-dipropionate-ointment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Calcipotriene and betamethasone dipropionate ointment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Calcipotriene and betamethasone dipropionate ointment (Calcipotriene and betamethasone dipropionate ointment) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical combination therapy (vitamin D analog + corticosteroid). Area: Dermatology.

marketed Topical combination therapy (vitamin D analog + corticosteroid) Vitamin D receptor (VDR) and glucocorticoid receptor (GR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Calcipotriene and betamethasone dipropionate ointment (Calcipotriene and betamethasone dipropionate ointment) — Galderma R&D. This combination ointment uses calcipotriene (a vitamin D analog) to normalize skin cell differentiation and betamethasone dipropionate (a potent corticosteroid) to reduce inflammation and immune activation in psoriatic plaques.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Calcipotriene and betamethasone dipropionate ointment TARGET	Calcipotriene and betamethasone dipropionate ointment	Galderma R&D	marketed	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
calcipotriene + clobetasol propionate	calcipotriene + clobetasol propionate	Leon Kircik, M.D.	marketed	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Daivobet® gel	Daivobet® gel	LEO Pharma	phase 3	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR); glucocorticoid receptor (GR)
Calcipotriene/betamethasone gel and ointment	Calcipotriene/betamethasone gel and ointment	LEO Pharma	phase 3	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR); glucocorticoid receptor (GR)
LEO 90105 = calcipotriol + betamethasone dipropionate	LEO 90105 = calcipotriol + betamethasone dipropionate	LEO Pharma	phase 3	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR); glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical combination therapy (vitamin D analog + corticosteroid) class)

LEO Pharma · 3 drugs in this class
Galderma R&D · 1 drug in this class
Leon Kircik, M.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Calcipotriene and betamethasone dipropionate ointment — Competitive Intelligence Brief. https://druglandscape.com/ci/calcipotriene-and-betamethasone-dipropionate-ointment. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab